September 09, 2008
Article
According to results of the Atorvastatin for Reduction of Myocardial Damage During Angioplasty-Acute Coronary Syndromes (ARMYDA-ACS) trial, short-term pretreatment with high-dose atorvastatin prior to percutaneous coronary intervention improves clinical outcome in subjects with unstable angina and non-ST-segment elevation myocardial infarction. These findings support the upstream administration of high-dose statins in subjects with acute coronary syndrome treated with an early invasive strategy.
Wonder Drake, MD: Sarcoidosis is a Disease of Exclusion
FDA Approves Dupilumab for Eosinophilic Esophagitis
New 52-Week Data Finds Guselkumab Well Tolerated in Moderate to Severe Psoriasis